

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 17/00, A61K 39/385		A1	(11) International Publication Number: WO 97/19957
			(43) International Publication Date: 5 June 1997 (05.06.97)
<p>(21) International Application Number: PCT/US96/18873</p> <p>(22) International Filing Date: 26 November 1996 (26.11.96)</p> <p>(30) Priority Data: 08/566,421 30 November 1995 (30.11.95) US</p> <p>(71) Applicant: NEW YORK UNIVERSITY [US/US]; 550 First Avenue, New York, NY 10016 (US)</p> <p>(72) Inventors: MERUELO, Daniel; 9 Country Club Lane, Scarborough, NY 10510 (US). OHNO, Kouichi; Apartment 6D, 1 Washington Square Village, New York, NY 10012 (US). LEVIN, Brandi, A.; 98-19 64th Avenue, Rego Park, NY 11374 (US).</p> <p>(74) Agents: POISSANT, Brian, M. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).</p>			
<p>(81) Designated States: AI, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(54) Title: HIGH EFFICIENCY TISSUE SPECIFIC COMPOUND DELIVERY SYSTEM USING STREPTAVIDIN-PROTEIN A FUSION PROTEIN</p> <p>(57) Abstract</p> <p>The invention relates to a method of delivering toxins or nucleic acids into specific cell types and to the complexes for the practice of the method. According to the invention, an antibody that recognizes a cell surface antigen is non-covalently bound to the antibody binding site of a ST-PA fusion protein; a biotinylated toxin or nucleic acid is bound to the biotin-binding site. In an alternative embodiment, the toxin or nucleic acid can be bound to a third biotinylated molecule, an adapter, which is bound to the biotin-binding site.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

High Efficiency Tissue Specific Compound Delivery System Using Streptavidin-Protein A Fusion Protein

1. INTRODUCTION

5 The present invention relates to methods and compositions that can be employed to introduce toxins and nucleic acids into the cytoplasm or nucleus of a eukaryotic cell, particularly a cell of a higher vertebrate. The invention allows for the efficient and specific delivery of 10 the toxins and nucleic acids into cells that bind an antibody. The invention particularly concerns the use of a fusion protein of streptavidin and protein A sequences to form a non-covalent complex of a toxin or nucleic acid and an antibody.

15 The invention provides a method of treatment of human disease by the introduction of toxins or antisense nucleotides into human cells, e.g., tumor cells, *in vivo* or *ex vivo*. The invention also provides methods of conducting biological research and methods useful in the production of 20 biological products by introducing exogenous duplex DNA molecules into cultured cells.

2. BACKGROUND OF THE INVENTION:

The selective introduction of compounds into the 25 cytoplasm or nucleus of specific cells has been a valuable technique in biological and medical research and in medical practice. Cell specific targeting of cytotoxins has been accomplished by complexing toxins with cell binding proteins that can preferentially bind targeted cells. The cell- 30 binding proteins of the complex can be either antibodies, particularly monoclonal antibodies, or protein ligands, e.g., /growth factors/ which recognize the corresponding surface antigens or receptor. Complexes of toxin and antibody have been termed immunotoxins.

35 Conventionally, the toxin and cell binding protein of the complex have been linked covalently through either chemical coupling or gene fusion. Conventional immunotoxins

have been made by chemically linking a toxin component to an antibody, typically a monoclonal antibody, with a heterobifunctional cross-linking reagent that is non-specific. Accordingly, this method yields a heterogeneous product in which some toxin molecules block the antibody's ability to bind antigen by linking to the F(ab) portion of the antibody. Additionally, the coupling chemistry can partially destroy the toxins activity.

Many of the problems associated with chemical conjugation have been overcome through the generation of single-chain fusion toxins using recombinant DNA technology. However, this technology requires that a new recombinant toxin for each target cell. The biological activity of each new recombinant toxin is unpredictable.

Alternative techniques have been developed in which the cytotoxin is non-covalently linked to the antibody or ligand. One such technique exploits the specific interaction between *Staphylococcal aureus* protein A and immunoglobulins to generate antibody complexes with two specificities.

According to this technique, protein A is complexed with antibodies of two different specificities: a toxin specific antibody and a cell surface specific antibody. Such complexes have been used to deliver ricin toxin into targeted cells (Laky, et al., 1986/1987, *Immunology Letters* 14:127-132). In a second immunotoxin targeting system, single chain antibodies are fused with streptavidin which has a strong and specific binding affinity for biotin. Using this construct, biotinylated toxin was delivered into a target cell (Dubel, et al., 1995, *Journal of Immunological Methods*, 178:201-209).

Recently, Sano et al. described a fusion protein consisting of streptavidin and one or two immunoglobulin G (IgG)-binding domains of protein A in *Escherichia coli*. (U.S. Patent 5,328,985, issued July 12, 1994, which is hereby incorporated by reference in its entirety). The streptavidin-protein A (ST-PA) fusion protein has functional biotin and IgG binding sites. Sano further described complexes of the streptavidin-protein A fusion protein, a

monoclonal antibody to BSA, and biotinylated horseradish peroxidase.

Sano also described a method of labeling cells using the ST-PA fusion protein. Cells were incubated with an antibody 5 to a cell surface antigen, Thy-1. The chimeric protein-biotinylated marker complex was subsequently added to the cell suspension. This technique was used to deliver biotinylated FITC to the surface of cells having Thy-1 antigen on their surface. However, Sano did not describe or 10 suggest the use of the ST-PA fusion protein to deliver compounds into the cytoplasm or nucleus of specific cells.

Immunotoxins appear to enter the cell via receptor-mediated endocytosis (Pastan et al., 1986, Cell 47:1-44 and Pirker et al., 1987, Lymphokines 14:361-382). Binding of the 15 antibody moiety of the immunotoxin complex to the surface receptor is followed by, first, clustering of the complex into coated pits and then by internalization of the complex into endosomes or receptosomes within the cell (Middlebrook et al., 1994, Microbiol. Rev., 48:199-221; Morris et al., 20 1985, Infect. Immun. 50:721-727; Fitzgerald et al., 1980, Cell 21:867-873). During the journey into the cell, the complex may be transported through different intracellular compartments that vary in pH and proteolytic enzyme activity before the toxins are translocated across an intracellular 25 membrane and into the cell cytoplasm where they can cause cell death.

A second area which has been developed concerns methods for introducing nucleic acids into cells. The most widely used methods employ calcium phosphate or DEAE-dextran to 30 promote uptake of nucleic acids. These methods appear to involve the steps of DNA attachment to the cell surface, entry into the cytoplasm by endocytosis, and subsequent transfer into the nucleus. Maniatis, Laboratory Cloning Manual, volume 2, 16.30. Depending upon the cell type, up to 35 20% of a population of cultured cells can take up DNA using calcium phosphate or DEAE-dextran.

Electroporation is an alternative transfection method in which an electric field is applied to open pores in the cell plasma membrane. DNA appears to enter the cell through these pores.

5 Liposomes have also been used to introduce nucleic acids into cells. According to this technique, artificial lipid-bilayer vesicles containing cationic and neutral lipids mediate the transfer of DNA or RNA into cells. The mechanism of liposome-mediated transfection, is not well understood, 10 but it appears that negatively charged phosphate groups on DNA bind to the positively charged surface of the liposome, and that the residual positive charge binds to negatively charged sialic acid residues on the cell surface.

Sano did not use the complex to introduce nucleic acid 15 into the cell. Sano et al. described DNA-antibody complexes with the ST-PA fusion protein by incorporating a single biotin molecule at one end of a linearized pUC 19 plasmid. In contrast to the methods of transfecting nucleic acids into the cell which are described above.

20

3. SUMMARY OF THE INVENTION:

The invention relates to a method of delivering toxins or nucleic acids into specific cell types and to the complexes for the practice of the method. According to the 25 invention, an antibody that recognizes a cell surface antigen is non-covalently bound to the antibody binding site of a ST-PA fusion protein; a biotinylated toxin or nucleic acid is bound to the biotin-binding site. In an alternative embodiment, the toxin or nucleic acid can be bound to a third 30 biotinylated molecule, an adapter, which is bound to the biotin binding-site.

In one embodiment of the present invention, a nucleic acid is delivered into a specific cell type. The nucleic acid can be a biotinylated single stranded nucleic acid bound 35 to the biotin binding site of the ST-PA fusion protein. In an alternative embodiment, the nucleic acid can be a duplex nucleic acid that forms a complementary triplex with a

biotinylated single stranded nucleic acid, which is in turn bound to the biotin binding site.

The method of the invention relates to the steps of forming a complex between a streptavidin-protein A fusion 5 protein; an antibody, that is specific for a cell surface protein, which undergoes endocytosis after binding with the antibody; and some targeted material e.g. a biotinylated multidrug resistance (mdr) gene product, prodrug, toxin or nucleic acid; isolating the complex from toxin that is not 10 bound to the biotin binding site; and exposing the target cell, to the complex so that the targeted material enters the cell.

3.1 DEFINITIONS:

15 As used herein,

toxin, refers to holotoxins, modified toxins, catalytic subunits of toxins, or any enzymes not normally present in a cell that under defined conditions cause the cell's death. A biotinylated toxin refers to a toxin that is either directly 20 biotinylated or one that is bound to a biotinylated adapter.

The term "antibody" refers to any molecule which contains one or more functional antigen binding domains and an Fc domain that specifically binds protein A.

25 4. BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1A. Schematic representation of immunotoxin or recombinant toxin binding to the corresponding surface antigen or receptor on the cell surface.

30 FIGURE 1B. Schematic representation of the streptavidin-protein A/biotinylated macromolecule complex binding to the corresponding surface antigen or receptor on the cell surface.

FIGURE 2. Comparison of the delivery of biotin- β galactosidase into A431 cells of an ST-PA/anti-EGFR 35 mAB/biotin- β galactosidase complex and an ST-TGF/biotin- β -galactosidase complex.

FIGURE 3. Time course analysis of cell β galactosidase staining after transfer of β galactosidase into the cells.

FIGURE 4A. Cell lines and cell surface molecules targeted by the ST-PA-biotin- β galactosidase-antibody complex.

FIGURE 4B. Transfer of ST-PA/mAb/biotin- β galactosidase into human cells, where the mAb is specific for HLA-DR, CD33, or CD34 cell surface molecules.

FIGURE 5. Schematic of the pAT- β galactosidase expression vector construct for forming triplex DNA with biotinylated poly(dT) oligonucleotide.

FIGURE 6A. Amino acid homology between fibronectin (SEQ ID NO:1) and streptavidin (SEQ ID NO:2). Bold type indicates homologous residues. The RGD and RYD domain of each protein is underlined. The sequence shown for fibronectin begins at residue 1481, and the streptavidin sequence begins at residue 49.

FIGURE 6B. Oligonucleotide primers DES (SEQ ID NO:3) and DER (SEQ ID NO:4) designed to modify the RYD sequence of the streptavidin gene.

FIGURE 6C. Schematic of the methodology to be used in modifying the RYD sequence of streptavidin.

5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

25 The present invention provides a method of specific delivery of targeted material, e.g., toxins, prodrugs, mdr gene products, or nucleic acids into cells by a complex of the targeted material, an antibody specific for a cell surface antigen on the cell, which antigen is endocytosed 30 when the cell is exposed to an effective concentration of the antibody, and a ST-PA fusion protein.

The streptavidin-protein A fusion protein (ST-PA) binds, non-covalently the cell specific antibody in the antibody binding site and the biotinylated targeted material in the 35 biotin binding site. The manner and method by which the targeted material is biotinylated is not critical; the

invention includes the use of any and all such methods and reagents.

In one embodiment, the invention provides a method for the specific destruction of cells, e.g., the destruction of tumor cells in a host or *ex vivo* in short term or long term culture. A toxin can be selected from the group consisting of: thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, 10 alpha-sarcin and cholera toxin. The toxin is biotinylated and the complex of PA-ST/Ab/biotinylated toxin is formed. An effective amount of the complex can then be administered to the host or to the *ex vivo* culture system.

In an alternative embodiment the invention provides a method of using an antibody to a cell to introduce into the cell a cytotoxic prodrug, i.e., a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. The embodiment contemplates the use of a complex of the ST-PA chimeric protein with a tumor selective 20 monoclonal antibody and prodrug. Compounds suitable as prodrugs include by way of example glutamyl derivative of a benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, and phenoxyacetamide derivative of doxorubicin.

25 A further embodiment of the invention contemplates a complex for the delivery of single stranded nucleic acid into cells. As used herein, the term "single stranded nucleic acid" refers to both naturally and non-naturally occurring nucleic acids. The nucleic acid to be delivered can be 30 biotinylated using any of the methods currently available, such as, random incorporation, extension reactions using DNA polymerase, and PCR with biotinylated primers. Such nucleic acids can be used to specifically destroy mRNAs to which they are complementary.

35 A further embodiment of the invention concerns the introduction into a cell of a duplex DNA that can integrate into the cell's genome or replicate episomally and that can

be transcribed. The direct incorporation of biotin into a duplex DNA can interfere with both replication and transcription of the DNA. To overcome these problems, the duplex DNA to be delivered into the cell is modified to 5 include a sequence that can form a region of triplex nucleic acid with a single stranded nucleic acid.

Triplex DNA formations have been described and typically consist of T-A-T and C-G-C nucleotide triads. The third strand of the triplex occupies the major groove of an A-form 10 DNA helix and forms Hoogsteen base pairs with the homopolymeric duplex DNA. Alternatively, a triplex can be formed with duplex DNA. As used herein, the term "triplex" refers to a structure formed by Hoogsteen base pairing between a duplex DNA and a single stranded nucleic acid.

15 In this embodiment, the complex contains a duplex DNA Hoogsteen paired to a single stranded nucleic acid, which is biotinylated and complexed with the ST-PA/mAb complex. The duplex DNA can be a linear duplex DNA, which is suitable for recombination into the genome of a cell or, alternatively, 20 the duplex can be a circular or supercoiled circular DNA, which can episomally replicate.

This embodiment of invention can be used under any circumstances it is desired to introduce cloned DNA into a cell, e.g., to express a product or to alter the phenotype of 25 the cell, to investigate the function of any cloned gene.

A further embodiment of the invention comprises a complex of an antibody to a cell surface protein found on an antigen presenting cell, the ST-PA fusion protein, and a biotinylated protein of a pathological bacteria or virus, 30 such a complex can be used to localize the antigen to antigen presenting cells and thereby enhance the immune response of CD4 positive T cells relative to that of other lymphocytes.

The complexes of the present invention can be formed by simply admixing ST-PA, a monoclonal antibody, and the 35 biotinylated material in the appropriate ratios. The components can be mixed in any order.

The ST-PA fusion protein forms tetramers which bind up to four biotinylated molecules and four IgG molecules, which are each bivalent. Without limitation as to theory, the octovalent binding of complexes of the invention to the cell surface is believed to cause the complexes to have superior binding and internalization properties compared to other immunotoxins and immunopharmaceutical complexes.

Biotin-blocked streptavidin is capable of specifically interacting with cell surfaces through an Arg-Tyr-Asp sequence present in the protein (the "RYD site"). This site is distinct from the biotin-binding cleft of the protein and bears high homology to the RGD-containing cell binding domain of fibronectin which mediates fibronectin-cell surface interactions (Alon et al, 1993, *Europ. J. Cell Biol.* 60: 1-11). Studies have suggested that streptavidin acts as a close mimetic of fibronectin (Alon et al, 1993, *Europ. J. Cell Biol.* 60: 1-11).

The conserved RYD and RGD domains of fibronectin and streptavidin function as universal recognition sequences for interactions with many membrane-bound receptors. In one embodiment of the invention, the streptavidin component of the complex can be modified to alter the RYD site. As used herein, the term "modified RYD sequence" includes any alteration to the RYD site or flanking region which eliminates the non-biotin binding site-related interaction of streptavidin with cell surface proteins. One such modification is the replacement of aspartic acid by glutamic acid.

30 6. EXAMPLES:

6.1 MATERIALS AND METHODS

Plasmid, pTSAPA-2, described in United States Patent 5,328,985, issued July 12, 1994, carries the chimeric gene of streptavidin and protein A (region E and D). Expression and 35 purification of the gene fusion of ST-PA was carried out according to the methods that follow.

Fusion Protein Preparation:

Bacterial Strain lysogen BL21 (DE3) (pLysS) was transformed with the pTSAPA-2 streptavidin-protein A fusion expression vector. The transformed strain was grown at 37°C 5 in LB media supplemented with 50 µg/ml ampicillin, 34 µg/ml chloramphenicol and .2% glucose. When the absorbance at 600 nm of the culture was between .8 and 1.0 OD, 100 mM isopropyl β -D-thiogalactopyranoside (IPTG) dissolved in water was added to a final concentration of .4 mM to induce 10 the T7 RNA polymerase gene placed under the lac UV5 promoter. After the induction, the cells were incubated at 37°C with shaking for 2 hours.

Purification of streptavidin-protein A fusion chimeric protein was carried out at 4°C or on ice unless otherwise 15 indicated. The culture (100 ml) of BL21 (DE3) (pLysS) (pTSAPA-2) incubated for 2 hours after the induction was centrifuged at 2,900 x g for 15 min. The cell pellet was suspended in 10 ml of 2 mM EDTA, 30 mM Tris-Cl (pH 8.0), 0.1% Triton X-100, 0.5 mM PMSF to lyse the cells and the lysate 20 was stored at -70°C until used. To the thawed cell lysate, PMSF, leupeptin, and pepstatin A were added to final concentrations of 0.5 mM, 1 µM, and 1 µM, respectively. The lysate was then treated with 10 µg/ml of deoxyribonuclease I and 10 µg/ml ribonuclease A in the presence of 12 mM MgSO₄ at 25 room temperature for 20 minutes. The mixture was centrifuged at 39,000 x g for 15 minutes and the pellet was dissolved in 100 ml of 7 M guanidine hydrochloride overnight at 4°C with stirring. After the pellet was dissolved the protein was then dialyzed against 150 mM NaCl, 50 mM Tris-Cl (pH 7.5), 30 0.05% Tween 20, 0.1 mM PMSF, 1 µM leupeptin, 1 µM pepstatin A, 0.02% NaN₃. To achieve slow removal of the guanidine hydrochloride, the dialysis bag containing the protein solution was left overnight in the dialysis solution (~1,000 ml) without stirring, followed by 3 changes of the dialysis 35 solution and dialysis with stirring at 4°C. The dialysate was centrifuged at 39,000 x g for 15 minutes, and the supernatant was applied to an IgG Sepharose 6 Fast Flow

column (1.2 x 1.1 cm) previously washed with 5-10 bed volumes of TST Buffer. The column was then equilibrated with 2-3 bed volumes of each: 1) 0.5 M Acetic acid, pH 3.4 (pH adjusted with NH₄CH₃COOH (NH₄Ac); 2) 150 mM NaCl, 50 mM Tris-Cl 5 (pH 7.5), 0.05% Tween 20 (TST Buffer); 3) 0.5 M Acetic Acid, pH 3.4; and 4) TST. The sample was applied to the column and the unbound protein was removed by washing the column with: 1) 10 bed volumes of TST, and 2) 2 bed volumes of 5 mM NH₄Ac, pH 5.0. Elution was performed with .5 M Acetic Acid, pH 3.4. 10 The eluate was collected in 1-2 ml fractions, and the fractions having the greatest OD at 280 were dialyzed against 1 M NaCl, 50 mM sodium carbonate (pH 11.0). The dialysate was clarified by centrifugation at 39,000 x g for 15 minutes, and applied to a 2-iminobiotin agarose column (1.2 x 1.2 c.m) 15 previously equilibrated with 1 M NaCl, 50 mM sodium carbonate (pH 11.0). After the unbound proteins were removed with the same solution, the bound proteins were eluted with 6 M urea, 50 mM ammonium acetate (pH 4.0). The eluted proteins were dialyzed against Tris-buffered saline [TBS; 150 mM NaCl, 20 20 mM Tris-Cl (pH 7.5)] containing 0.02% NaN₃, and the dialysate was stored at 4°C after filtration through a 0.22 µm filter (Millex-GV, Millipore).

Formation of the ST-PA/mAb/biotinylated β -Galactosidase

25 complex:

A mixture of ~2 µg of antibody, ~28 µg of fusion protein, and ~2 units of biotinylated β -Galactosidase was incubated at room temperature for at least 10 minutes. After this incubation, the complex is ready to use.

30

β -Galactosidase Staining: (X-GAL Staining)

β -Galactosidase staining of cells that adhere to the plate was performed according to Sanes, et al., 1986, EMBO J. 5: 3133-3142.

35

The protocol of Molecular Probes, Inc. was used to detect lacZ β -Galactosidase gene expression in cells that grow in suspension.

The above protocols were used to determine if the complex that contains the antibody coupled to the fusion protein and the biotinylated β -Galactosidase enzyme was successfully transduced into the cell of choice. If the 5 transduction was complete, the cells were blue after overnight incubation.

2) Modification of streptavidin protein RYD sequence.

Biotin-blocked streptavidin binds specifically ($K_d = 3 \times 10^{-6} M$) to cell surfaces, presumably via an RYD containing sequence that is distinct from the biotin-binding cleft of the protein.

Alternation of the RYD domain (sequence) to other amino acid residues is expected to eliminate the non-biotin related 15 specific surface binding of a large variety of cells.

One way to modify the RYD sequence would be to change the RYD sequence to RYE. The change of RYD sequence to RYE can be achieved by introducing a point mutation using sequential PCR steps. This can be achieved by designing two 20 primers, DES (SEQ ID NO:1) and DER (SEQ ID NO:2) (See Figure 5) and using the pTSAPA-2 expression vector as a template of the streptavidin gene. First, PCR is carried out using two pairs of primers: T7 promoter/DER and T7 terminator/DES.

Second, the two amplified DNA fragments are then purified and 25 pooled into one sample. A second round of PCR is then performed using the pooled purified products of the first round as templates and the T7 promoter and T7 terminator primers. The mutated RYE sequence in the streptavidin gene component is confirmed through sequence analysis of the 30 product of the second round of PCR.

3) Delivery of biotin- β -galactosidase into A431 cells.

In order to study the ability of ST-PA to deliver compounds into a cell, the delivery of this complex was 35 compared with that of a complex in which core streptavidin was covalently linked to the TGF α receptor.

pTSA-TGF α , an expression vector for streptavidin-TGF- α (ST-TGF) was constructed by replacing the gene of protein A - in pTSAPA-2 with a mature human TGF- α gene (amino acids 1-50).

5 To demonstrate the capability of ST-PA and ST-TGF α fusion proteins to deliver biotinylated protein into specific cells types, biotinylated β -galactosidase was complexed with the streptavidin component of the fusion protein. Delivery of β -galactosidase into A431 cells was quantitated using
10 known staining techniques and FACS analysis.

ST-PA/ biotin β -galactosidase was complexed with anti-EGFR mAb and the resulting complex was then incubated with A431 human epidermoid cells over-expressing epidermal growth factor receptor (EGFR). Alternatively, ST-TGF was mixed with
15 biotin- β -galactosidase and the resulting complex was administered to A431 cells.

As shown in Figure 2, ST-PA fusion protein efficiently delivered biotin- β -galactosidase into A431 cells through EGFR on its surface (positive cells >99%). The ST-TGF α fusion
20 protein also displayed efficient delivery of biotin- β -galactosidase into A431 cells (positive cells >99%). Surprisingly, the amount of biotin- β -galactosidase delivered into each cell by the ST-TGF α fusion protein was lower than that observed in the ST-PA delivery system (the mean
25 fluorescence activity observed was 214 and 2402, respectively).

The highly efficient delivery by ST-PA fusion protein of biotin- β -galactosidase into A431 cells may be due to the four binding sites for biotin and IgG contained on each ST-PA
30 tetramer (Figure 1B). In a time course experiment shown in Figure 3, more than 99% of cells demonstrated positive staining for β -galactosidase up to 2 days after transfer of biotin- β -galactosidase into the cell.

4) Delivery of biotin β -galactosidase into cells using mAbs of different specificity.

The experimental procedure applied in studying the delivery of biotin β -galactosidase into A431 cells was also used to study the delivery of the antibody/ST-PA/biotinylated β -galactosidase complex into other cell types. The study utilized antibodies that recognize several different cell surface molecules. The cell lines and cell surface molecules used in this experiment are summarized in Figure 4A. As shown in Figure 4B, the ST-PA/mAb complex was highly efficient (positive cells >99%) in transferring β -galactosidase into the human cell types tested by way of the HLA-DR, CD33 and CD34 molecules present on the surface of these cells.

15

5) pAT- β -galactosidase expression vector.

Although biotin can be incorporated into DNA (e.g. expression plasmids), random incorporation of biotin into DNA may result in a loss of transcriptional activity. In order to retain the transcriptional activity of the DNA to be introduced into the cell, a new gene transfer system was developed which utilizes a pAT-expression vector having a poly(dA)/ poly(dT) tract downstream of the expression cassette (Figure 5). According to this transfer system, the DNA to be delivered into the cell is cloned into the expression vector. The pAT-expression vector forms triplex DNA with a biotinylated poly(dT) oligonucleotide which binds to the biotin binding site of the ST-PA fusion protein. The antibody bound to the antibody binding site of the ST-PA fusion protein targets the cells into which the DNA is to be delivered.

The protocol for triplex DNA formation and DNA transfer of the β -galactosidase gene into cells is as follows. The β -galactosidase gene is cloned into the expression cassette of the pAT-expression vector (Figure 5). The mixture of 4 μ g of pAT- β -galactosidase expression vector and 20 pmol of Biotinylated poly(dT) oligonucleotide (Promega) in TMN buffer

(10 mM Tris, pH 8.0, 10mM MgCl₂, 50mMNaCl), is incubated at 37°C for 1 hour. ST-PA fusion protein (0.5 µg) and mAb (1.0-µg) are then added to the mixture and the resulting admixture is incubated at room temperature for 30 minutes. The triplex 5 DNA-ST-PA-mAb complex is added to the cells (1 X 10⁶) and incubated at 37°C for 48 hours. β-galactosidase activity is detected by FACS.

References

10 Sano, T. and Cantor, C.R. 1991. A streptavidin-protein A chimera that allows one-step production of a variety of specific antibody conjugates. Bio/Technol. 9:1378-1381.

Pastan, I. and FitzGerald, D. 1991. Recombinant toxins for 15 cancer treatment. Science. 254:1173-1177.

Goshorn, S.C., Svensson, H.P., Kerr, D.E., Somerville, J.E., Senter, P.D. and Fell, H.P. 1993. Genetic construction, expression, and characterization of a single chain 20 anticarcinoma antibody fused to b-lactamase. Cancer Res. 53:2123-2127.

Siegall, C.B., Xu, Y.-H., Chaudhary, V.K., Adhya, S., FitzGerald, D. and Pastan, I. 1989. Cytotoxic activities of 25 a fusion protein comprised of TGFα and *pseudomonas* exotoxin. FASEB J. 3:2647-2652.

Ghetie, M.-A., Laky, M., Moraru, I. and Ghetie, V. 1986. Protein A vectorized toxins-I. Preparation and properties of 30 protein A-Ricin toxin conjugates. Mol. Immunol. 23:1373-1379.

Kiyama, R., Nishikawa, N. and Oishi, M. 1994. Enrichment of human DNAs that flank poly(dA). poly(dT) tract by triplex DNA formation. J. Mol. Biol. 237:193-200.

Ito, T., Smith, C.L. and Cantor, C.R. 1992. Sequence-specific DNA purification by triplex affinity capture. Proc.Natl.Acad.Sci. USA 89:495-498.

5 Alon R., E. Bayer, M. Wilchek, 1993, Cell Adhesion to streptavidin via RGD-dependent integrins, European Journal of Cell Biology 60: 1-11.

10

15

20

25

30

35

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: M ruelo, Daniel
Ohno, Kouichi
Levin, Brandi

(ii) TITLE OF INVENTION: High Efficiency Tissue Specific Compound
Delivery System Using Streptavidin-Protein A Fusion
Protein

(iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pennie and Edmonds
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: U.S.A.
(F) ZIP: 10036-2711

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Poissant, Brian M.
(B) REGISTRATION NUMBER: 28,462
(C) REFERENCE/DOCKET NUMBER: 8105-007

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (212) 790-9090
(B) TELEFAX: (212) 869-8864
(C) TELEX: 66441 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Tyr	Thr	Ile	Thr	Val	Tyr	Ala	Val	Thr	Gly	Arg	Gly	Asp	Ser	Pro	Ala
1				5					10						15
Ser	Ser	Lys	Pro												
				20											

(2) INFORMATION FOR SEQ ID NO:2:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asn Ala Glu Ser Arg Tyr Val Leu Thr Gly Arg Tyr Asp Ser Ala Pro
1 5 10 15
Ala Thr Asp Gly Ser
20

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGTTACGAAA GCGCCCCG

18

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TGGGCAATGC TTTCG

15

WE CLAIM:

1. A complex for transferring a toxin into a cell, - which comprises:

5 (a) a streptavidin-protein A fusion protein having an antibody binding site and a biotin binding site;

10 (b) an antibody, bound to the antibody binding site, in which the antibody is specific for a cell surface protein, and in which the cell surface protein undergoes endocytosis after binding with the antibody; and

15 (c) a biotinylated toxin, bound to the biotin binding site.

2. The complex of claim 1, in which the toxin is selected from the group consisting of:

20 (a) thymidine kinase;

(b) endonuclease;

(c) RNase;

(d) alpha toxin;

25 (e) ricin;

(f) abrin;

(g) *Pseudomonas* exotoxin A;

(h) diphtheria toxin;

(i) saporin;

30 (j) momordin;

(k) gelonin;

(l) pokeweed antiviral protein;

(m) alpha-sarcin; and

(n) cholera toxin.

35 3. A complex for transferring a prodrug into a cell, which comprises:

35 (a) a streptavidin-protein A fusion protein having an antibody binding site and a biotin binding site;

(b) an antibody, bound to the antibody binding site, in which the antibody is specific for a cell

surface protein, and in which the surface protein undergoes endocytosis after binding with the antibody; and

5 (c) a biotinylated prodrug, bound to the biotin binding site.

4. A complex for transferring a MDR gene product into a cell, which comprises:

10 (a) a streptavidin-protein A fusion protein having an antibody binding site and a biotin binding site;

15 (b) an antibody, bound to the antibody binding site, in which the antibody is specific for a cell surface protein, and in which the surface protein undergoes endocytosis after binding with the antibody; and

20 (c) a biotinylated MDR gene product, bound to the biotin binding site.

5. A complex for transferring a single stranded nucleic acid into a cell, which comprises:

25 (a) a streptavidin-protein A fusion protein having an antibody binding site and a biotin binding site;

(b) an antibody, bound to the antibody binding site, in which the antibody is specific for a cell surface protein, and in which the surface protein undergoes endocytosis after binding with the antibody; and

30 (c) a biotinylated single stranded nucleic acid, bound to the biotin binding site.

6. A complex for transferring a duplex nucleic acid into a cell, which comprises:

35 (a) a streptavidin-protein A fusion protein having an antibody binding site and a biotin binding site;

(b) an antibody, bound to the antibody binding site, in which the antibody is specific for a cell surface protein, and in which the surface protein

undergoes endocytosis after binding with the antibody;

- (c) a biotinylated single stranded nucleic acid, having a homopurine or homopyrimidine portion, bound to the biotin binding site; and
- (d) a double stranded DNA that forms triplex structure with the biotinylated single stranded nucleic acid.

7. A complex for transferring protein of a pathological bacteria or virus into a cell, which comprises:

- (a) a streptavidin-protein A fusion protein having an antibody binding site and a biotin binding site;
- (b) an antibody, bound to the antibody binding site, in which the antibody is specific for a cell antigen presenting cell surface protein, and in which the cell surface protein undergoes endocytosis after binding with the antibody; and
- (c) a biotinylated protein of a pathological bacteria or virus, bound to the biotin binding site.

20

8. The complex of claim 1, 3, 4, 5, 6, or 7 in which there are four antibody binding sites and four biotin binding sites.

25

9. The complex of claim 1, 3, 4, 5, 6, or 7 in which the streptavidin component of said streptavidin-protein A fusion protein has a modified RYD sequence.

30

10. The complex of claim 1, 3, 4, 5, 6, or 7 which further comprises an antibody that binds transferrin receptor.

35

11. The complex of claim 1, 3, 4, 5, or 6, wherein the antibody recognizes a surface antigen selected from the group of:

- (a) HLA-DR;
- (b) CD33;

- (c) CD34; and
- (d) EGF receptor.

12. The complex of claim 1, 3, 4, 5, 6, or 7
5 in which the antibody is an IgG antibody.

13. A pharmaceutical composition, comprising:
(a) the complex of claim 1, 3, 4, 5, 6, or 7, and
(b) a pharmaceutically acceptable carrier,
10 which composition is substantially free of toxin not bound to
the streptavidin-protein A fusion protein.

14. A method for transferring toxin into a cell,
which comprises the steps of:

15 (a) forming a complex comprising
i) a streptavidin-protein A fusion protein
having an antibody binding site and a biotin
binding site;
ii) an antibody, bound to the antibody binding
site, in which the antibody is specific for
a cell surface protein, and in which the
surface protein undergoes endocytosis after
binding with the antibody; and
iii) a biotinylated toxin, bound to the biotin
binding site;
20 (b) isolating the complex from toxin that is not
bound to the biotin binding site; and
25 (c) exposing the isolated complex to a cell, so that
the toxin enters the cell.

30 15. A method for transferring material into a cell,
which comprises the steps of:

35 (a) forming a complex comprising
i) a streptavidin-protein A fusion protein
having an antibody binding site and a biotin
binding site;

16. A method for transferring double stranded DNA
15 into a cell, which comprises the steps of:

(a) forming a complex comprising:

- i) a streptavidin-protein A fusion protein having an antibody binding site and a biotin binding site;
- 20 ii) an antibody, bound to the antibody binding site, in which the antibody is specific for a cell surface protein, and in which the surface protein undergoes endocytosis after binding with the antibody;
- 25 iii) a biotinylated single stranded nucleic acid, bound to the biotin binding site; and
- iv) a double stranded DNA that forms triplex structure with the biotinylated single stranded nucleic acid; and

30 (b) exposing the complex to a cell, so that the double stranded DNA enters the cell.

17. The method of claim 14, 15 or 16, wherein the complex has four antibody binding sites and four biotin binding sites.

18. The method of claim 14, 15, or 16, wherein streptavidin component of said streptavidin-protein A fusion protein has a modified RYD sequence.

5 19. The method of claim 14, 15, or 16, wherein the complex further comprises an antibody that binds transferrin receptor.

20. The method of claim 14, 15, or 16, wherein the 10 antibody recognizes a surface antigen selected from the group of:

- (a) HLA-DR;
- (b) CD33;
- (c) CD34; and
- 15 (d) EGF receptor.

21. The method of claim 14, 15, or 16, wherein the antibody is an IgG antibody.

20

25

30

35

1/8




FIG. 1A




FIG. 1B

SUBSTITUTE SHEET (RULE 26)





FIG. 2A

FIG. 2B
SUBSTITUTE SHEET (RULE 26)




FIG. 2C






FIG. 3
SUBSTITUTE SHEET (RULE 26)

4/8

NAME	CELL TYPE	SURFACE MOLECULE
DAUDI	BURKITT LYMPHOMA	HLA-DR
HL-60	PROMYELOCYTIC LEUKEMIA	CD33
KG1	ACUTE MYELOGENOUS LEUKEMIA	CD34

FIG.4A

FIG.5
SUBSTITUTE SHEET (RULE 26)




FIG. 4B




FIG. 4C

SUBSTITUTE SHEET (RULE 26)





FIG. 4D

FIG. 4E
SUBSTITUTE SHEET (RULE 26)




FIG. 4F




FIG. 4G

8/8


FIBRONECTIN
STREPTAVIDINYTITVYAV-TGRGDS-PASSKP
NAESRY-VLTGRYDSAPATDGSSEQ ID NO:1
SEQ ID NO:2

FIG.6A

PRIMER DES: 5'-CGT TAC GAA AGC GCC CCG-3' SEQ ID NO:3
 R Y E

PRIMER DER: 3'-TGG GCA ATG CTT TCG-5' SEQ ID NO:4

FIG.6B



MIX PCR PRODUCT A AND B
 2nd PCR USING T7 PROMOTER PRIMER AND T7 TERMINATOR PRIMER

PCR PRODUCT WHICH HAS A POINT MUTAION

FIG.6C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/18873

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) C07K 17/00; A61K 39/385
US CL : 530/402; 424/193.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/402; 424/193.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SANO et al. A streptavidin-protein A chimera that allows one-step production of a variety of specific antibody conjugates. Bio/technology. December 1991, Vol. 9, pages 1378-1381. See entire document.	1-2, 8-14, 17-21
Y	LAMBERT et al. An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Research. 01 December 1991, Vol. 51, pages 6236-6242. See entire document.	1-2, 14

Further documents are listed in the continuation of Box C.

See patent family annex.

•	Special categories of cited documents:	
•A*	document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•E*	earlier document published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•O*	document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family
•P*	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 JANUARY 1997

Date of mailing of the international search report

26 MAR 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer

MINH-TAM B. DAVIS

Telephone No. (703) 308-0916

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/18873

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ARTEAGA et al. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α -Pseudomonas exotoxin 40 fusion protein. <i>Cancer Research</i> . 01 September 1994, Vol. 54, pages 4703-4709. See entire document.	1-2, 11, 14, 20
Y	MCGRAW et al. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. <i>Cancer Immunol. Immunother.</i> 1994, Vol. 39, pages 367-374. See entire document.	1-2, 11, 14
Y	ALON et al. Streptavidin contains an RYD sequence which mimics the RGD receptor domain of fibronectin. <i>Biochemical and Biophysical Research Communications</i> . 16 August 1990, Vol. 170, No. 3, pages 1236-1241. See entire document.	18
Y	OZAWA et al. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. <i>Int. J. Cancer</i> . 1989, Vol. 43, pages 152-157. See entire document.	1-2, 11, 14, 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/18873

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **Claims Nos.:**
because they relate to subject matter not required to be searched by this Authority, namely:

2. **Claims Nos.:**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. **Claims Nos.:**
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please see extra sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-2, 8-14, 17-21

Remark on Protest

<input type="checkbox"/>
<input type="checkbox"/>

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees

INTERNATIONAL SEARCH REPORT

international application No.

PCT/US96/18873

BOX II Observations where unity of invention is lacking.

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1

Group I, claim(s) 1-2, 8-14, 17-21, sharing the inventive concept of a complex of streptavidin-protein A fusion protein bound to an antibody and a biotinylated toxin, a pharmaceutical composition, and a method of transferring a toxin into a cell.

Group II, claim(s) 3, 8-13, sharing the inventive concept of a complex of streptavidin-protein A fusion protein bound to an antibody and a biotinylated prodrug, and a pharmaceutical composition..

Group III, claim(s) 4, 8-13, sharing the inventive concept of a complex of streptavidin-protein A fusion protein bound to an antibody and a biotinylated MDR gene product, and a pharmaceutical composition.

Group IV, claims 5, 8-13, sharing the inventive concept of a complex of streptavidin-protein A fusion protein bound to an antibody and a biotinylated single stranded nucleic acid, and a pharmaceutical composition.

Group V, claims 6, 8-13, sharing the inventive concept of a complex of streptavidin-protein A fusion protein bound to an antibody and a biotinylated double stranded nucleic acid, and a pharmaceutical composition.

Group VI, claims 7, 8-13, sharing the inventive concept of a complex of streptavidin-protein A fusion protein bound to an antibody and a protein of a pathological bacteria or virus, and a pharmaceutical composition.

Group VII, claims 15, 17-21, sharing the inventive concept of a method of transferring a single stranded DNA, a MDR gene product and a prodrug into a cell.

Group VIII, claims 16, 17-21, sharing the inventive concept of a method of transferring a double stranded DNA into a cell.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

In the instant case the shared inventive concept would appear to be the central core of X-streptavidin-protein A-antibody, wherein X is selected from the group consisting of toxins, prodrugs, MDR, single stranded DNA, triplex DNA, and bacterial or viral protein.

If the central core is anticipated or obvious in view of the art then there is no unity. It appears that Sano, 1991 alone or in combination with Lambert, 1991 defeats unity. Therefore, the invention of claims 1-21 do not fulfill the requirements for unity of invention, and each member of the group X forms basis of an individual group.

Thus, the invention lacks unity because rule 13 does not provide for multiple products or multiple methods of use within a single application.

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG. Search terms: streptavidin, protein A, conjugate or fusion, toxin, deliver or transfer, single stranded or double stranded DNA, prodrug, MDR, CD33, epidermal growth factor receptor.